Patents by Inventor Wilfred Jefferies

Wilfred Jefferies has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12011421
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Grant
    Filed: November 8, 2021
    Date of Patent: June 18, 2024
    Assignee: CAVA HEALTHCARE INC.
    Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
  • Patent number: 11925678
    Abstract: Methods for diagnosing and treating Alzheimer's disease are provided. In particular, methods of restoring blood-brain barrier integrity and/or promoting vascular reversion in a person suffering from Alzheimer's disease by administering an anti-angiogenic agent or an agent that is capable of restoring tight junction integrity. Methods of preventing or delaying the onset of Alzheimer's disease in a subject are also provided.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: March 12, 2024
    Assignee: Cava Healthcare Inc.
    Inventors: Wilfred Jefferies, Kaan E. Biron, Dara L. Dickstein
  • Publication number: 20230405026
    Abstract: The present invention relates to methods of immune modulation. In particular, the present invention relates to regulation of neuroinflammation by modulation of ABCF1. Modulation of ABCF1 may be useful in the MDD.
    Type: Application
    Filed: November 5, 2021
    Publication date: December 21, 2023
    Inventor: Wilfred Jefferies
  • Publication number: 20230402129
    Abstract: The present invention provides a method of epitope-based vaccine design. The method comprising: a) providing one or more target amino acid sequence(s); b) optionally discarding peptides based on one or more predetermined features; c) parsing and selecting MHC I and/or MHC II binding peptides from said sequences; and d) assembling the MHC I and/or MHC II binding peptides optionally with linkers to produce an assembly of peptides.
    Type: Application
    Filed: November 23, 2021
    Publication date: December 14, 2023
    Inventors: Wilfred Jefferies, Paolo Ribeca
  • Publication number: 20220226440
    Abstract: The present invention provides methods of modulating of cancer immunity using type 2 innate lymphoid cells (ILC2s), interleukin 33 (IL-33), IFI44 or combination thereof. Also provided are methods of preventing tumor metastasis and/or cancer progression by treatment with therapies comprising type 2 innate lymphoid cells (ILC2s), interleukin 33 (IL-33), IFI44 or combination thereof. Also provided are diagnostic methods for assessing cancer prognosis.
    Type: Application
    Filed: November 19, 2021
    Publication date: July 21, 2022
    Inventors: Wilfred Jefferies, Iryna Yuriyivna Saranchova
  • Publication number: 20220105051
    Abstract: An object of the present invention is to provide a compound for modulating expression of Major Histocompatibility Complex Class I (MHC-1) and/or TAP-1, in eukaryotic cells. In certain aspects, the compound is a curcuphenol, a terpene or a cannabinoid. Also provided are a composition that comprises the compound and methods of use thereof, for instance, for augmenting an immune response involving MHC-1 CTL, treating cancer, or treating a disease associated with histone acetylation abnormalities.
    Type: Application
    Filed: January 30, 2020
    Publication date: April 7, 2022
    Applicant: Cava Healthcare Inc.
    Inventors: Wilfred Jefferies, Samantha Ellis, Ray Anderson, Sarah Dada, Ping Cheng, Cheryl Pfeifer, David Williams, Lilian Nohara
  • Publication number: 20220062195
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Application
    Filed: November 8, 2021
    Publication date: March 3, 2022
    Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
  • Patent number: 11213571
    Abstract: The present invention provides methods of modulating of cancer immunity using type 2 innate lymphoid cells (IL-C2s), interleukin 33 (IL-33), IFI44 or combination thereof. Also provided are methods of preventing tumor metastasis and/or cancer progression by treatment with therapies comprising type 2 innate lymphoid cells (ILC2s), interleukin 33 (IL-33), IFI44 or combination thereof. Also provided are diagnostic methods for assessing cancer prognosis.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: January 4, 2022
    Assignee: CAVA HEALTHCARE INC.
    Inventor: Wilfred Jefferies
  • Patent number: 11197832
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: December 14, 2021
    Assignee: Cava Healthcare Inc.
    Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
  • Publication number: 20210100881
    Abstract: Methods for diagnosing and treating Alzheimer's disease are provided. In particular, methods of restoring blood-brain barrier integrity and/or promoting vascular reversion in a person suffering from Alzheimer's disease by administering an anti-angiogenic agent or an agent that is capable of restoring tight junction integrity. Methods of preventing or delaying the onset of Alzheimer's disease in a subject are also provided.
    Type: Application
    Filed: September 18, 2020
    Publication date: April 8, 2021
    Inventors: Wilfred Jefferies, Kaan E. Biron, Dara L. Dickstein
  • Publication number: 20200375917
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Application
    Filed: August 20, 2020
    Publication date: December 3, 2020
    Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
  • Patent number: 10792347
    Abstract: Methods for diagnosing and treating Alzheimer's disease are provided. In particular, methods of restoring blood-brain barrier integrity and/or promoting vascular reversion in a person suffering from Alzheimer's disease by administering an anti-angiogenic agent or an agent that is capable of restoring tight junction integrity. Methods of preventing or delaying the onset of Alzheimer's disease in a subject are also provided.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: October 6, 2020
    Assignee: Alternative Extracts Inc.
    Inventors: Wilfred Jefferies, Kaan E. Biron, Dara L. Dickstein
  • Patent number: 10751296
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: August 25, 2020
    Assignee: CAVA HEALTHCARE INC.
    Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
  • Patent number: 10058619
    Abstract: Provided are conjugates between p97 (melanotransferrin) and polynucleotides such as small interfering RNA (siRNA) molecules, and related compositions and methods of use thereof, for instance, to facilitate delivery of polynucleotides such as siRNA molecules across the blood-brain barrier (BBB) and/or improve their tissue penetration in CNS and/or peripheral tissues, and thereby treat and/or diagnose various diseases, including those having a central nervous system (CNS) component.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: August 28, 2018
    Assignee: Bioasis Technologies, Inc.
    Inventors: Wilfred Jefferies, Reinhard Gabathuler
  • Publication number: 20170319508
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Application
    Filed: January 25, 2017
    Publication date: November 9, 2017
    Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
  • Publication number: 20170224792
    Abstract: Methods for diagnosing and treating Alzheimer's disease are provided. In particular, methods of restoring blood-brain barrier integrity and/or promoting vascular reversion in a person suffering from Alzheimer's disease by administering an anti-angiogenic agent or an agent that is capable of restoring tight junction integrity. Methods of preventing or delaying the onset of Alzheimer's disease in a subject are also provided.
    Type: Application
    Filed: April 25, 2017
    Publication date: August 10, 2017
    Inventors: Wilfred Jefferies, Kaan E. Biron, Dara L. Dickstein
  • Publication number: 20170049897
    Abstract: Provided are conjugates between p97 (melanotransferrin) and polynucleotides such as small interfering RNA (siRNA) molecules, and related compositions and methods of use thereof, for instance, to facilitate delivery of polynucleotides such as siRNA molecules across the blood-brain barrier (BBB) and/or improve their tissue penetration in CNS and/or peripheral tissues, and thereby treat and/or diagnose various diseases, including those having a central nervous system (CNS) component.
    Type: Application
    Filed: May 1, 2015
    Publication date: February 23, 2017
    Inventors: Wilfred Jefferies, Reinhard Gabathuler
  • Publication number: 20160053237
    Abstract: The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2/neu-expressing and Her1/EGFR-expressing cancers.
    Type: Application
    Filed: August 27, 2015
    Publication date: February 25, 2016
    Applicant: BIOASIS TECHNOLOGIES, INC.
    Inventors: Wilfred Jefferies, Timothy Z. Vitalis, Reinhard Gabathuler
  • Patent number: 9161992
    Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: October 20, 2015
    Assignee: biOasis Technologies, Inc.
    Inventors: Wilfred Jefferies, Mei Mei Tian, Timothy Vitalis
  • Publication number: 20150283226
    Abstract: Compositions for and methods of stimulating a MHC I mediated immune response comprising stimulating MHC I endolysosomal cross presentation in dendritic cells. Stimulation MHC I endolysosomal cross presentation may comprise over-expression CD74 in dendritic cells and/or targeting antigens to the MHC I endolysosomal cross presentation pathway. Fusion proteins comprising an antigen or fragment thereof and a CD74 endolysosomal targeting sequence are also provided.
    Type: Application
    Filed: July 31, 2012
    Publication date: October 8, 2015
    Applicant: bioMmune Technologies Inc.
    Inventors: Wilfred Jefferies, Genc Basha, Kyla Omilusik, Ana Chavez-Steenbock